Donald Benjamin Sanders

Conference Muscle Nerve · May 2026 INTRODUCTION/AIMS: Azathioprine (AZA) and mycophenolate mofetil (MMF) are the most commonly used non-steroidal immunosuppressants in patients with generalized myasthenia gravis (gMG) in North America but their relative effectiveness among disease subgroups ... Full text Link to item Cite

275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands.

Conference Neuromuscul Disord · November 2024 The 275th ENMC workshop on the diagnosis and management of seronegative myasthenia gravis (SNMG) was held on February 9-11, 2024. The participants included experts in the field of adult and pediatric MG together with patient representatives. This workshop ... Full text Link to item Cite

Pregnancy in MuSK-positive myasthenia gravis: A single-center case series.

Conference Muscle Nerve · July 2023 INTRODUCTION/AIMS: Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. Our objective in this study was to describe the course of MMG during pregnancy and within 6 months po ... Full text Link to item Cite

The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes.

Conference Muscle Nerve · April 2023 INTRODUCTION/AIMS: The Duke Myasthenia Gravis (MG) Clinic Registry contains comprehensive physician-derived data on patients with MG seen in the Duke MG Clinic since 1980. The aim of this study was to report outcomes in patients seen in the clinic and trea ... Full text Link to item Cite

THE DUKE MYASTHENIA GRAVIS REGISTRY: II. ANALYSIS OF OUTCOMES

Conference MUSCLE & NERVE · September 2022 Link to item Cite

THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS

Conference MUSCLE & NERVE · May 2022 Link to item Cite

THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: THYMECTOMY IN MUSK MYASTHENIA

Conference MUSCLE & NERVE · May 2022 Link to item Cite

RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERTEATON MYASTHENIC SYNDROME (LEMS)

Conference MUSCLE & NERVE · October 1, 2015 Link to item Cite

Results of a Double-Blind Placebo-Controlled Study of 3,4-Diaminopyridine (DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

Conference ANNALS OF NEUROLOGY · October 1, 2015 Link to item Cite

T CELL REACTIVITY IN INCLUSION BODY MYOSITIS (IBM)

Conference MUSCLE & NERVE · September 1, 2015 Open Access Link to item Cite

PARALLEL CLINICAL AND JITTER CHANGES DURING RAPID, ECULIZUMAB-INDUCED MYASTHENIC REMISSION

Conference MUSCLE & NERVE · October 1, 2014 Link to item Cite

COMPARISON OF B10 CELLS IN IMMUNOSLTPPRESSED AND IMMUNOSUPPRESSION NAIVE ACHR plus MG

Conference MUSCLE & NERVE · October 1, 2014 Link to item Cite

THE EFFECTS OF TIRASEMTIV, A FAST SKELETAL MUSCLE TROPONIN ACTIVATOR, ON MEASURES OF RESPIRATORY FUNCTION IN NEUROMUSCULAR DISEASES

Conference MUSCLE & NERVE · September 1, 2014 Link to item Cite

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.

Conference Muscle Nerve · July 2014 INTRODUCTION: We determined health plan paid costs and healthcare resource usage of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from ... Full text Link to item Cite

PROLONGED B CELL DEPLETION IN MUSK MYASTHENIA GRAVIS FOLLOWING RITUXIMAB TREATMENT

Conference MUSCLE & NERVE · October 1, 2013 Link to item Cite

DOES THE PRESENCE OR LEVEL OF ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) PREDICT GENERALIZATION IN OCULAR MYASTHENIA (OM)?

Conference MUSCLE & NERVE · October 1, 2012 Link to item Cite

Correlation of acetylcholine receptor antibody binding, modulating and blocking activity with jitter measurements in myasthenia gravis

Conference NEUROLOGY · March 1997 Link to item Cite

Do acetylcholine receptor antibody binding, modulating and blocking activity measurements correlate with disease severity in myasthenia gravis?

Conference NEUROLOGY · March 1997 Link to item Cite

Donald Benjamin Sanders

Scholarly Works - Conferences

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands.

Pregnancy in MuSK-positive myasthenia gravis: A single-center case series.

The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes.

THE DUKE MYASTHENIA GRAVIS REGISTRY: II. ANALYSIS OF OUTCOMES

THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS

THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: THYMECTOMY IN MUSK MYASTHENIA

RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERTEATON MYASTHENIC SYNDROME (LEMS)

Results of a Double-Blind Placebo-Controlled Study of 3,4-Diaminopyridine (DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

T CELL REACTIVITY IN INCLUSION BODY MYOSITIS (IBM)

PARALLEL CLINICAL AND JITTER CHANGES DURING RAPID, ECULIZUMAB-INDUCED MYASTHENIC REMISSION

COMPARISON OF B10 CELLS IN IMMUNOSLTPPRESSED AND IMMUNOSUPPRESSION NAIVE ACHR plus MG

THE EFFECTS OF TIRASEMTIV, A FAST SKELETAL MUSCLE TROPONIN ACTIVATOR, ON MEASURES OF RESPIRATORY FUNCTION IN NEUROMUSCULAR DISEASES

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.

PROLONGED B CELL DEPLETION IN MUSK MYASTHENIA GRAVIS FOLLOWING RITUXIMAB TREATMENT

DOES THE PRESENCE OR LEVEL OF ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) PREDICT GENERALIZATION IN OCULAR MYASTHENIA (OM)?

DOES THE ACETYLCHOLINE RECEPTOR ANTIBODY LEVEL PREDICT OR CORRELATE WITH THE OUTCOME IN MG?

DOES CHANGE IN ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) LEVEL PREDICT OR CORRELATE WITH CLINICAL CHANGE IN MG?

PLASMA EXCHANGE COMPLICATIONS ARE RELATED TO THE VENOUS ACCESS ROUTE

INCREASED OCCURRENCE OF LATE ONSET MYASTHENIA GRAVIS

DO ANTIBODIES PREDICT THE PRESENCE OR ABSENCE OF THYMOMA IN MYASTHENIA GRAVIS?

Prognostic Value of Clinical Response to Acetylcholinesterase Inhibitors in Myasthenia Gravis with Anti-MuSK Antibodies

IN65-FR-02 Rationale for thymectomy in myasthenia gravis

Muscle-specific kinase antibody myasthenia gravis: Response to treatment in 25 patients

Lambert-Eaton myasthenic syndrome: Findings in 97 patients

Correlation of acetylcholine receptor antibody binding, modulating and blocking activity with jitter measurements in myasthenia gravis

Do acetylcholine receptor antibody binding, modulating and blocking activity measurements correlate with disease severity in myasthenia gravis?